Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells.
An aberrant T cell population is the basis for diagnosis of refractory coeliac disease and determines the risk of enteropathy-associated T cell lymphoma. This disease is serious with a poor survival. Pathogenetic mechanisms sustaining aberrant T cell proliferation remain unknown. Recently, alemtuzumab has been proposed as a promising new approach to treat these patients. Only few single cases have been tested at present; nevertheless, in all the cases a clinical improvement was observed. However, whether intraepithelial lymphocytes have been targeted effectively by alemtuzumab is still debated. This study reports, using two-dimensional difference gel electrophoresis (2D DIGE), hyperexpressed proteins associated specifically with aberrant T cells found in a patient with coeliac disease by comparison of the protein expression of this sample with that of patients with coeliac disease and polyclonal T cells or with control subjects. The data demonstrated a significantly higher expression of IgM, apolipoprotein C-III and Charcot-Leyden crystal proteins in a duodenal biopsy specimen of the patient with clonal T cells compared with that of other patients. These preliminary results allow hypothesizing different clinical effects of alemtuzumab in patients with coeliac disease and aberrant T cell proliferation, because as well as the probable effect on T cells, alemtuzumab could exert its effect by acting on inflammatory associated CD52(+) IgM(+) B cells and eosinophil cells, known to produce IgM and Charcot-Leyden crystal proteins, that we demonstrated to be altered in this patient. The results also emphasize the possible association of apolipoprotein with aberrant T cell proliferation.
De Re
V
V
Farmacologia Sperimentale e clinica, Centro di Riferimento Oncologico, Aviano (PN), Italy. vdere@cro.it
Simula
M P
MP
Caggiari
L
L
Orzes
N
N
Spina
M
M
Da ponte
A
A
De Appollonia
L
L
Dolcetti
R
R
Canzonieri
V
V
Cannizzaro
R
R
D000328:Adult; D053305:Apolipoprotein C-III / Q000378:metabolism*; D002446:Celiac Disease / Q000276:immunology*; D004386:Duodenum / Q000276:immunology; D004591:Electrophoresis, Polyacrylamide Gel / Q000379:methods; D005260:Female; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007075:Immunoglobulin M / Q000378:metabolism*; D008245:Lysophospholipase / Q000378:metabolism*; D008875:Middle Aged; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D053305:Apolipoprotein C-III; D006023:Glycoproteins; D007075:Immunoglobulin M; D016692:Receptors, Antigen, T-Cell, gamma-delta; D008245:Lysophospholipase; C011711:lysolecithin acylhydrolase